Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
Teesha Downton,Fiona Zhou,Davendra Segara,Rinath Jeselsohn,Elgene Lim
DOI: https://doi.org/10.2147/DDDT.S380925
2022-09-03
Abstract:Teesha Downton, 1, 2 Fiona Zhou, 1, 2 Davendra Segara, 1 Rinath Jeselsohn, 3, &ast Elgene Lim 1, 2, &ast 1 Garvan Institute of Medical Research, Sydney, NSW, Australia; 2 School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia; 3 Dana-Farber Cancer Institute, Boston, MA, USA &astThese authors contributed equally to this work Correspondence: Elgene Lim, Tel +61 2 9355 5600, Fax +61 2 9355 5602, Email Several endocrine therapies are currently available for the treatment of estrogen receptor (ER) positive breast cancer, but the clinical benefit of these agents is limited by endocrine therapy drug resistance. A common mechanism of endocrine therapy resistance is ESR1 mutations. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has activity against ESR1 mutant tumors but requires intramuscular injection and has poor bioavailability that precludes optimal drug dosing. This led to the development of second-generation SERDs which are potent and have improved oral bioavailability and pharmacokinetics. Several of these oral SERDs are now in phase III trials in both the early and advanced ER positive breast cancer settings. This review summarizes the background of oral SERD development, the current status and future perspectives. Keywords: selective estrogen receptor degraders, breast cancer, estrogen receptor Breast cancer is the most common cancer diagnosed globally, 1 and more than 70% of breast cancers are estrogen receptor (ER) positive and human epidermal growth factor-2 (HER2) negative. 2 Endocrine therapy (ET) forms the backbone of systemic therapy for these cancers. Currently available ET agents include luteinizing hormone-releasing hormone (LHRH) agonists, selective estrogen receptor modulators (SERMs) such as tamoxifen, aromatase inhibitors (AIs) including letrozole, anastrozole, and exemestane, and the first-generation selective estrogen receptor degrader (SERD) fulvestrant. This review summarizes the history and current status of a novel group of new ET agents, the oral, second-generation SERDs, several of which are already in advanced stages of clinical development. In the 1980s, a series of steroidal 7α-alkylamide analogs of 17β-estradiol were developed that had pure antagonist actions at the ER, in contrast to tamoxifen which has mixed ER agonist and antagonist actions. 3 The lead compound in this series was ICI 164,384 which achieved 89% ligand-ER binding affinity, 4 disrupted ligand-ER dimerization, 5 completely blocked trophic action of estradiol in the rat uterus 6 and increased ER turnover in the cytoplasm via ER protein degradation and reduced ER half-life. 7,8 However, ICI 164,384 had poor in vivo potency and was subsequently modified by fluorinating the terminal alkyl group and substituting the amide moiety in the 7α-side chain with polar groups, to produce ICI 182,780. 3 ICI 182,780 competes with estradiol to bind at the ER, and subsequently inhibit ER dimerization, increase ER degradation, and reduce ER translocation to the nucleus and ER target gene transcription. 9 The side chain of ICI 182,780 was designed long enough with at least 15 atoms to interact with the coactivator binding groove of ER, interfering with recruitment of coactivators for gene transcription. 10,11 Compared with ICI 164,384 and tamoxifen, ICI 182,780 had greater ER binding affinity and inhibited the growth of ER positive breast cancer cells to a greater extent in vitro and in vivo. In animal studies, ICI 182,780 demonstrated poor oral bioavailability, and improved potency was achieved by administering the drug as a subcutaneous arachis oil depot. 3 ICI 182,780 was later renamed fulvestrant and formulated with castor oil and alcohols for intramuscular injection. Fulvestrant was approved for clinical use in 2002 as a 4-weekly 250 mg intramuscular injection, after it was shown to be non-inferior to anastrozole in post-menopausal women with advanced breast cancer who had progressed on first-line ET, which in the majority of cases was tamoxifen at that time. 12,13 With this dose regimen though, steady-state plasma concentrations were not reached for several months leaving patients vulnerable to early disease progression. 14 Preoperative studies also suggested that greater efficacy could be achieved with a higher dose, as fulvestrant reduced ER and progesterone receptor (PR) expression and Ki67 scores in a dose-dependent manner, 15,16 and lack of change in these markers were seen with the -Abstract Truncated-